Significant Findings from HIF-2a Inhibitor Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: Newsfilter
- Clinical Outcome Link: The study is the first to demonstrate that the HIF-2a inhibitor casdatifan significantly suppresses serum erythropoietin (EPO) in patients with metastatic renal cell carcinoma, correlating with higher response rates and longer progression-free survival (PFS), indicating its potential clinical benefits.
- Survival Data: In the pooled analysis of four monotherapy cohorts (n=121) from the ARC-20 study, patients treated with casdatifan achieved a median PFS of 12.2 months, despite most having undergone multiple prior standard treatments, showcasing the drug's efficacy.
- Efficacy Validation: In the 100mg once-daily cohort, the confirmed objective response rate was 35%, with 60% of patients remaining progression-free at 12 months, further validating casdatifan's potential in kidney cancer treatment.
- Safety Analysis: Casdatifan exhibited a favorable safety profile across all doses, with common adverse events being anemia and hypoxia, and no patients discontinued treatment due to anemia, supporting its acceptable safety characteristics for further clinical exploration.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RCUS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RCUS
Wall Street analysts forecast RCUS stock price to fall
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 29.980
Low
14.00
Averages
27.44
High
44.00
Current: 29.980
Low
14.00
Averages
27.44
High
44.00
About RCUS
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Significant Findings from HIF-2a Inhibitor Study
- Clinical Outcome Link: The study is the first to demonstrate that the HIF-2a inhibitor casdatifan significantly suppresses serum erythropoietin (EPO) in patients with metastatic renal cell carcinoma, correlating with higher response rates and longer progression-free survival (PFS), indicating its potential clinical benefits.
- Survival Data: In the pooled analysis of four monotherapy cohorts (n=121) from the ARC-20 study, patients treated with casdatifan achieved a median PFS of 12.2 months, despite most having undergone multiple prior standard treatments, showcasing the drug's efficacy.
- Efficacy Validation: In the 100mg once-daily cohort, the confirmed objective response rate was 35%, with 60% of patients remaining progression-free at 12 months, further validating casdatifan's potential in kidney cancer treatment.
- Safety Analysis: Casdatifan exhibited a favorable safety profile across all doses, with common adverse events being anemia and hypoxia, and no patients discontinued treatment due to anemia, supporting its acceptable safety characteristics for further clinical exploration.
See More
Arcus Biosciences Grants Stock Options to New Employees
- Stock Option Grant: Arcus Biosciences has granted stock options totaling 18,400 shares to two new employees at an exercise price of $28.18 per share, based on the closing price on June 23, 2026, aimed at incentivizing new hires and enhancing their sense of belonging to the company.
- Restricted Stock Units: Additionally, the company awarded 9,250 shares in restricted stock units, further strengthening the long-term incentive mechanism for employees, promoting shared growth with the company, and enhancing team cohesion and stability.
- Incentive Plan Background: The stock grants are made under the 2020 Inducement Plan approved by the company’s Board of Directors in January 2020, complying with the
See More
Arcus Biosciences Grants Employee Stock Options
- Stock Option Grant: Arcus Biosciences' Compensation Committee granted one new employee options to purchase 2,850 shares at an exercise price of $23.32, reflecting the company's commitment to talent retention and incentive strategies.
- Restricted Stock Units: The employee also received 1,450 restricted stock units, which not only enhances employee loyalty but may also increase their commitment to the company's long-term growth.
- Inducement Plan Context: This grant was made under the company's 2020 Inducement Plan, approved by the Board in January 2020, demonstrating compliance with NYSE regulations and the company's proactive approach to attracting and retaining talent.
- Strategic Development: Arcus Biosciences focuses on developing differentiated molecules for cancer and autoimmune diseases, and with multiple clinical trials underway, the company's market competitiveness and innovation capabilities are expected to further strengthen.
See More
Arcus Biosciences Partners with Bristol Myers Squibb for Clinical Trial
- Clinical Trial Collaboration: Arcus Biosciences has entered into a clinical trial collaboration with Bristol Myers Squibb, supplying its investigational small-molecule HIF-2a inhibitor casdatifan for evaluation in the BMS-sponsored ROSETTA RCC-208 clinical trial, aimed at assessing its efficacy in advanced renal cell carcinoma.
- New Treatment Arms: The collaboration will add casdatifan combinations as two new arms of the ROSETTA RCC-208 trial, aiming to provide patients with treatment options based on HIF-2a inhibitors, thereby enhancing the effectiveness of existing therapies.
- Development Rights Retained: Under the agreement, both Arcus and Bristol Myers Squibb will retain development and commercial rights to their respective assets, ensuring independence while advancing their research agendas through this partnership.
- Strategic Development Plan: This collaboration is part of Arcus's holistic development strategy, designed to offer physicians and patients multiple treatment options, including first-line and second-line therapies, to address the treatment needs of advanced renal cell carcinoma.
See More
Arcus Biosciences Q1 2026 Earnings Call Insights
- R&D Spending Adjustment: Arcus Biosciences anticipates a significant reduction in R&D spending for 2026 and 2027, primarily due to the wind-down of the Dom project and decreased spending on quemli, which will help optimize resource allocation and enhance financial flexibility.
- Revenue Guidance Increase: Management raised the 2026 GAAP revenue guidance from $45 million to $55 million to a new range of $50 million to $65 million, reflecting an optimistic outlook on market demand and indicating confidence in revenue growth.
- Cash Flow Status: As of the end of the quarter, Arcus reported cash reserves of $876 million, with expectations to maintain approximately $600 million by the end of 2026, providing ample funding for operations over the next two years.
- Clinical Trial Progress: The enrollment pace for the PEAK-1 study is accelerating, with completion expected by the end of 2026, which will provide strong support for the company's competitive position in the kidney cancer market and lay the groundwork for subsequent clinical research.
See More
Arcus Biosciences Grants Employee Stock Options
- Stock Option Grant: Arcus Biosciences granted stock options to a new employee for 4,200 shares at an exercise price of $25.13, reflecting the company's commitment to talent and confidence in future growth.
- Restricted Stock Units: The employee also received 2,100 restricted stock units, which not only enhances employee loyalty but also incentivizes contributions to the company's long-term success.
- Incentive Plan Context: This grant is made under the company's 2020 Inducement Plan, approved by the Board, indicating a strategic focus on attracting and retaining talent.
- Company Development Vision: Arcus Biosciences is dedicated to developing innovative therapies for cancer and autoimmune diseases, aiming to expedite the development of its late-stage drug portfolio through collaborations, showcasing significant market potential.
See More
Significant Findings from HIF-2a Inhibitor Study
- Clinical Outcome Link: The study is the first to demonstrate that the HIF-2a inhibitor casdatifan significantly suppresses serum erythropoietin (EPO) in patients with metastatic renal cell carcinoma, correlating with higher response rates and longer progression-free survival (PFS), indicating its potential clinical benefits.
- Survival Data: In the pooled analysis of four monotherapy cohorts (n=121) from the ARC-20 study, patients treated with casdatifan achieved a median PFS of 12.2 months, despite most having undergone multiple prior standard treatments, showcasing the drug's efficacy.
- Efficacy Validation: In the 100mg once-daily cohort, the confirmed objective response rate was 35%, with 60% of patients remaining progression-free at 12 months, further validating casdatifan's potential in kidney cancer treatment.
- Safety Analysis: Casdatifan exhibited a favorable safety profile across all doses, with common adverse events being anemia and hypoxia, and no patients discontinued treatment due to anemia, supporting its acceptable safety characteristics for further clinical exploration.
See More
Arcus Biosciences Grants Stock Options to New Employees
- Stock Option Grant: Arcus Biosciences has granted stock options totaling 18,400 shares to two new employees at an exercise price of $28.18 per share, based on the closing price on June 23, 2026, aimed at incentivizing new hires and enhancing their sense of belonging to the company.
- Restricted Stock Units: Additionally, the company awarded 9,250 shares in restricted stock units, further strengthening the long-term incentive mechanism for employees, promoting shared growth with the company, and enhancing team cohesion and stability.
- Incentive Plan Background: The stock grants are made under the 2020 Inducement Plan approved by the company’s Board of Directors in January 2020, complying with the
See More
Arcus Biosciences Grants Employee Stock Options
- Stock Option Grant: Arcus Biosciences' Compensation Committee granted one new employee options to purchase 2,850 shares at an exercise price of $23.32, reflecting the company's commitment to talent retention and incentive strategies.
- Restricted Stock Units: The employee also received 1,450 restricted stock units, which not only enhances employee loyalty but may also increase their commitment to the company's long-term growth.
- Inducement Plan Context: This grant was made under the company's 2020 Inducement Plan, approved by the Board in January 2020, demonstrating compliance with NYSE regulations and the company's proactive approach to attracting and retaining talent.
- Strategic Development: Arcus Biosciences focuses on developing differentiated molecules for cancer and autoimmune diseases, and with multiple clinical trials underway, the company's market competitiveness and innovation capabilities are expected to further strengthen.
See More
Arcus Biosciences Partners with Bristol Myers Squibb for Clinical Trial
- Clinical Trial Collaboration: Arcus Biosciences has entered into a clinical trial collaboration with Bristol Myers Squibb, supplying its investigational small-molecule HIF-2a inhibitor casdatifan for evaluation in the BMS-sponsored ROSETTA RCC-208 clinical trial, aimed at assessing its efficacy in advanced renal cell carcinoma.
- New Treatment Arms: The collaboration will add casdatifan combinations as two new arms of the ROSETTA RCC-208 trial, aiming to provide patients with treatment options based on HIF-2a inhibitors, thereby enhancing the effectiveness of existing therapies.
- Development Rights Retained: Under the agreement, both Arcus and Bristol Myers Squibb will retain development and commercial rights to their respective assets, ensuring independence while advancing their research agendas through this partnership.
- Strategic Development Plan: This collaboration is part of Arcus's holistic development strategy, designed to offer physicians and patients multiple treatment options, including first-line and second-line therapies, to address the treatment needs of advanced renal cell carcinoma.
See More
Arcus Biosciences Q1 2026 Earnings Call Insights
- R&D Spending Adjustment: Arcus Biosciences anticipates a significant reduction in R&D spending for 2026 and 2027, primarily due to the wind-down of the Dom project and decreased spending on quemli, which will help optimize resource allocation and enhance financial flexibility.
- Revenue Guidance Increase: Management raised the 2026 GAAP revenue guidance from $45 million to $55 million to a new range of $50 million to $65 million, reflecting an optimistic outlook on market demand and indicating confidence in revenue growth.
- Cash Flow Status: As of the end of the quarter, Arcus reported cash reserves of $876 million, with expectations to maintain approximately $600 million by the end of 2026, providing ample funding for operations over the next two years.
- Clinical Trial Progress: The enrollment pace for the PEAK-1 study is accelerating, with completion expected by the end of 2026, which will provide strong support for the company's competitive position in the kidney cancer market and lay the groundwork for subsequent clinical research.
See More
Arcus Biosciences Grants Employee Stock Options
- Stock Option Grant: Arcus Biosciences granted stock options to a new employee for 4,200 shares at an exercise price of $25.13, reflecting the company's commitment to talent and confidence in future growth.
- Restricted Stock Units: The employee also received 2,100 restricted stock units, which not only enhances employee loyalty but also incentivizes contributions to the company's long-term success.
- Incentive Plan Context: This grant is made under the company's 2020 Inducement Plan, approved by the Board, indicating a strategic focus on attracting and retaining talent.
- Company Development Vision: Arcus Biosciences is dedicated to developing innovative therapies for cancer and autoimmune diseases, aiming to expedite the development of its late-stage drug portfolio through collaborations, showcasing significant market potential.
See More
